Back

Treatment effect of selexipag on time to disease progression when initiated early in pulmonary arterial hypertension (PAH) patients: GRIPHON and TRITON pooled analysis

27 August 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Pulmonary arterial hypertension: risk stratification guides for new treatments and informed outcomes Pulmonary Hypertension ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor John G Coghlan

Royal Free Hospital, London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Non-invasive risk prediction based on right ventricular function in patients with pulmonary arterial hypertension
Mrs V. Qaderi (Hamburg, DE)
Abstract Slides Video
Presentation thumbnail
Inclusion of echocardiographic measure of right ventricular function in the non-invasive French pulmonary arterial hypertension risk stratification method
Doctor C. Fauvel (Rouen, FR)
Abstract Slides Video
Presentation thumbnail
Twenty-year experience and outcomes in a national paediatric pulmonary hypertension service
Doctor A. Constantine (Birmingham, GB)
Abstract Slides Video
Presentation thumbnail
Safety, tolerability, and pharmacokinetics (PK) of treprostinil palmitil inhalation powder (TPIP): a phase 1, randomised, double-blind, single- and multiple-dose study
Doctor F. Ismat (Bridgewater, US)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary arterial hypertension: risk stratification guides for new treatments and informed outcomes

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources